1. Skip to navigation
  2. Skip to content
  3. Skip to sidebar

CRA Releases New APA Report

On January 10, 2013, the Canada Revenue Agency released its 2011-2012 Advance Pricing Arrangement Program Report (previous reports are available here).

This is the eleventh year in which the CRA has issued such a report, which is generally intended to enhance taxpayer awareness of the APA program and to describe (i) current operational status, (ii) relevant changes, and (iii) issues that may affect the program in future years.

The general purpose of an APA is to create certainty between the taxing authorities of Canada and a foreign country concerning the transfer pricing of cross-border intercompany transactions.  In the absence of an APA governing such transactions, taxpayers may be exposed to higher audit risk relating to their intercompany transfer pricing methodologies, which may ultimately result in costly and time-consuming negotiations with the multiple tax authorities as well as potential litigation. Accordingly, the CRA encourages taxpayers to avail themselves of the APA program to mitigate the transfer pricing risk in the appropriate circumstances, particularly where the taxpayer engages in intercompany transactions of a recurring nature (i.e., frequent sale of goods between affiliates or the ongoing provision of intercompany services).

The APA program has proven popular with taxpayers over the years and the number of applicants continues to grow – the 2011-2012 fiscal year had the highest number of applicants to the program (34) since the 2007-2008 fiscal year.  The inventory of unresolved cases also continues to grow (the inventory increased from 96 at the end of the 2010-2011 fiscal year to 102 at the end of the 2011-2012 fiscal year).  In the 2011-2012 fiscal year, 17 new cases were admitted to the APA program whereas only 10 cases were completed (and one was withdrawn).  The large discrepancy between the number of applicants and the number of cases formally admitted to the program in the year is partially a reflection of the changes introduced by the CRA beginning in the 2010-2011 fiscal year requiring that taxpayers invest significantly more time and resources during the initial application/due diligence phase of the APA process and to provide a greater amount of financial and business information prior to acceptance into the program.  This results in a longer and more extensive “screening” process but is intended to eliminate inappropriate cases before they are accepted into the program inventory.

Other highlights of the Report include:

  • The average amount of time required to conclude a bilateral APA from acceptance into the program until completion was 44 months, which appears generally consistent with prior years;
  • The majority of APA’s relate to the cross-border transfer of tangible property.  Approximately 47% of APA cases in process relate to tangible personal property whereas cases involving tangible personal property and intra-group services represent approximately 31% and 22% of cases in process;
  • The transactional net margin method (“TNMM”) continues to be the most frequently used transfer pricing methodology in APA cases; and
  • APAs involving the United States represent approximately 71% of all APA cases that are in process (which is slightly lower than the percentage of completed APA cases that involve the United States).

, , ,

CRA Releases New APA Report

Arguments conclude in first transfer pricing case heard by the Supreme Court of Canada: GlaxoSmithKline Inc. v. The Queen

On Friday morning January 13, 2012, the Supreme Court of Canada heard arguments in GlaxoSmithKline Inc. v. The Queen. See our earlier posts on the case here and here.

By way of background, Glaxo Canada purchased ranitidine, the active pharmaceutical ingredient in Zantac, a branded ulcer medication, from a non-arm’s-length non-resident. In 1990-1993, Glaxo Canada paid approximately $1,500 per kg of ranitidine, while generic purchasers of ranitidine were paying approximately $300 per kg. The Minister of National Revenue reassessed Glaxo Canada under former section 69 of the Income Tax Act on the basis that the taxpayer had overpaid for the ranitidine in light of the fact that generic manufacturers were paying considerably less for the same ingredient.

The issue before the Tax Court was whether the amount paid by the taxpayer to the non-arm’s-length party was “reasonable in the circumstances.” The Tax Court held that (a) the “comparable uncontrolled price” (or CUP) method was the most accurate way to determine the arm’s-length price for ranitidine and (b) the appropriate comparable transactions were the purchases of ranitidine by the generic manufacturers. Subject to a relatively minor adjustment, the Tax Court dismissed the taxpayer’s appeal.

The Federal Court of Appeal allowed the taxpayer’s appeal. The Court of Appeal held that the lower court had erred in its application of the “reasonable in the circumstances” test, and that it should have inquired into the circumstances that an arm’s-length purchaser in the taxpayer’s position would have considered relevant in deciding what reasonable price to pay for ranitidine. The Court of Appeal set aside the lower court judgment and sent the matter back to the Tax Court to be reconsidered.

The Crown appealed and Glaxo Canada cross-appealed the portion of the order sending the matter back to the Tax Court. The appeal was heard by a seven-member panel of the Court (Chief Justice McLachlin, Justice Dechamps, Justice Abella, Justice Rothstein, Justice Cromwell, Justice Moldaver and Justice Karakatsanis).

The Crown argued that the analysis under subsection 69(2) required a “stripping away” of the surrounding circumstances of the transaction in question and, in particular, the license agreement pursuant to which Glaxo Canada was entitled to market and sell the drug ranitidine under the brand name Zantac.  Having done that, the only relevant comparator was the price of ranitidine on the “open market”, namely, the price paid for ranitidine by generic drug manufacturers.

The Court asked a number of questions about whether subsection 69(2) (with its reference to “in the circumstances”) makes the ultimate use of the ranitidine relevant to the analysis. Several judges asked whether it made a difference that the ranitidine purchased by Glaxo Canada was to be marketed and sold as Zantac, a branded product that would yield a higher retail price than the equivalent generic product.  Justices Abella and Rothstein were particular active during this discussion.

In stark contrast to the Crown’s position, Glaxo Canada contended that the only question to be answered under subsection 69(2) was whether two arm’s-length parties, sitting across a boardroom table, would arrive at the same deal that was concluded by Glaxo Canada and its non-resident parent company. Justice Abella wondered if, even in those circumstances, an arm’s-length party would pay $1,500 for a kilogram of ranitidine.

Chief Justice McLachlin asked about bundling and its relationship to transfer pricing – if the $1,500/kg price included an amount paid for something other than ranitidine why was it not identified by Glaxo Canada as such and why was withholding tax not remitted thereon under section 212 of the Act? Counsel for Glaxo Canada responded by making two points: First, if a portion of the price paid by Glaxo Canada for ranitidine were more properly characterized as royalties, for example, such amounts would be expenses to Glaxo Canada and thus there was no mischief from a transfer pricing perspective in bundling them into the cost of the goods. Second, it is not the policy or practice of the CRA to require taxpayers to unbundle intellectual property or other intangibles from tangible property as, presumably, the practical burden imposed by such a requirement would be difficult to overstate. It was unclear whether the tension between the issues of bundling and arm’s-length pricing was resolved at the hearing.

In a nutshell, the choice before the Court is this: Is the fact that the ranitidine purchased by Glaxo Canada was destined to become Zantac relevant to the analysis under subsection 69(2)? Glaxo contends that it is, while the Crown contends that it is not.

On the cross-appeal, Glaxo Canada argued that it had met the case against it on the pleadings and the matter should, therefore, have concluded at the Federal Court of Appeal and should not have been sent back to the Tax Court. There were a number of questions from the bench on that point.

The panel reserved judgment on both the appeal and cross-appeal.

, , , , ,

Arguments conclude in first transfer pricing case heard by the Supreme Court of Canada: GlaxoSmithKline Inc. v. The Queen

Transfer Pricing Case Opens in the Tax Court of Canada – McKesson Canada Corporation v. The Queen

A transfer pricing trial commenced on October 17, 2011, in the Tax Court of Canada in Toronto.  Mr. Justice Patrick Boyle will decide whether paragraph 247(2)(a) of the Income Tax Act (the “Act”) applies to the transaction at issue (the factoring of accounts receivable) to reduce the deduction of an amount paid by a Canadian corporation to a non-resident affiliate which assumed the risks of collecting the Canadian corporation’s accounts receivable.  The agreed-upon discount rate was 2.2% but the Minister of National Revenue (the “Minister”) says it would have been just over 1% had the parties been dealing at arm’s length.  The trial is expected to take approximately 6-7 weeks.  The hearing began on Monday, October 17, 2011 with an opening statement by counsel for the Appellant, McKesson Canada Corporation (“McKesson Canada”).

McKesson Canada contracted to sell its accounts receivable to a related, non-resident company, McKesson International Holdings III S.à R.L. (“McKesson International”). McKesson Canada and McKesson International agreed to a variable discount rate that would be applied to the accounts receivable.  The rate was calculated using a formula that resulted in a discount rate of 2.2% for the 2003 taxation year.  According to the terms of the agreement, all bad debt risk relating to the accounts receivable that were sold was assumed by McKesson International. The discount rate was intended to compensate McKesson International for assuming the risk that some of the accounts receivable may not be collected and would have to be written off.

The Minister disallowed a portion of the amounts deducted by McKesson Canada in respect of the discount on the sale of accounts receivable. The Minister determined that, based on the terms and conditions in the agreement, the discount rate that would have been agreed upon had the parties dealt with one another at arm’s length would not have exceeded 1.0127%. Accordingly, the Minister added some $26 million to the Appellant’s income for its 2003 taxation year, reflecting a discount rate of 1.0127% rather than the rate of 2.2% as agreed by the parties.

In his opening statement, counsel for McKesson Canada contended that the issue should be whether the discount rate agreed upon by the parties was appropriate for an arm’s length transaction given the amount of risk that was being transferred from the vendor to the purchaser of the accounts receivable and that the issue should not be what the discount rate should be if the principal terms of the contract were changed to reflect some other hypothetical agreement used by the Minister for purposes of his assessment.

In addition to the Part I appeal, there is a Part XIII appeal as well. The issue there is whether McKesson Canada conferred a benefit on its controlling shareholder, McKesson International, under subsection 15(1) of the Act by selling certain of it accounts receivable and, therefore, whether McKesson Canada should be deemed to have paid a dividend to McKesson International under paragraph 214(3)(a) of the Act. Including interest, the Part XIII assessment is approximately $1.9 million.

In conclusion, counsel for McKesson Canada argued that the Part XIII assessment is barred by virtue of the Canada-Luxembourg Income Tax Convention (1999) (the “Treaty”), which is applicable since McKesson International is a company existing under the laws of Luxembourg. As Article 9(3) of the Treaty includes a five year time limit for changes by Canada to the income of a taxpayer, the time for the adjustment expired on March 29, 2008 (before the Part XIII assessment was mailed).

The hearing continues.

For the link to the Part I Notice of Appeal, click here.

For the link to the Part I Amended Reply, click here.

For the link to the Part XIII Amended Notice of Appeal, click here.

For the link to the Part XIII Reply, click here.

, , , , , , ,

Transfer Pricing Case Opens in the Tax Court of Canada – McKesson Canada Corporation v. The Queen

GlaxoSmithKline’s Factum Filed in the Supreme Court of Canada: Stage Set for Transfer Pricing Battle on January 13, 2012 (Tentative Date)

GlaxoSmithKline’s factum has now been filed with the Supreme Court of Canada addressing the arguments set out earlier in the Crown’s factum.  There are no particular surprises.

As noted in our earlier blog post, the Crown was granted leave to appeal the Federal Court of Appeal’s decision and GSK was granted leave to cross-appeal. The Crown contends in its factum that the FCA gave short shrift to the arm’s length principle which it was required to apply under subsection 69(2) of the Income Tax Act as developed in the OECD Guidelines. The Crown argues that the FCA has replaced the arm’s length standard with a “reasonable business person” test.

In its factum, GSK argues that the approach taken by the FCA in determining “reasonable in the circumstances” is consistent with the OECD Guidelines which call for the application of the arm’s length principle in light of the actual business circumstances faced by the taxpayer. Neither subsection 69(2) of the Income Tax Act nor the arm’s length principle require courts to ignore the circumstances of the marketplace. GSK also says that the Crown’s approach effectively reads out the phrase “in the circumstances” as used in subsection 69(2) of the Income Tax Act.

Finally, by way of cross-appeal, GSK takes issue with the FCA’s order that the matter be re-heard by the Tax Court of Canada, contending that that the FCA ought simply to have set the assessments aside.

, ,

GlaxoSmithKline’s Factum Filed in the Supreme Court of Canada: Stage Set for Transfer Pricing Battle on January 13, 2012 (Tentative Date)